| 1601 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
8 |
| 1602 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
12 |
| 1603 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
8 |
| 1604 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
52 |
| 1605 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
57 |
| 1606 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
66 |
| 1607 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
5 |
| 1608 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
54 |
| 1609 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
56 |
| 1610 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
3 |
| 1611 |
Bone Marrow |
Allogeneic |
Adrenoleukodystrophy |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1612 |
Bone Marrow |
Allogeneic |
Adrenoleukodystrophy |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1613 |
Bone Marrow |
Allogeneic |
Adrenoleukodystrophy |
Hematology |
2024 |
Standard Therapy |
Poland |
9 |
| 1614 |
Bone Marrow |
Allogeneic |
B-Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1615 |
Bone Marrow |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2024 |
Standard Therapy |
Poland |
4 |
| 1616 |
Bone Marrow |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2024 |
Standard Therapy |
Poland |
41 |
| 1617 |
Bone Marrow |
Allogeneic |
Chronic Lymphocytic Leukemia Richter Transformation |
Hematology |
2024 |
Standard Therapy |
Poland |
55 |
| 1618 |
Bone Marrow |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
67 |
| 1619 |
Bone Marrow |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
12 |
| 1620 |
Bone Marrow |
Allogeneic |
Diffuse Large B-Cell Lymphoma |
Hematology |
2024 |
Standard Therapy |
Poland |
61 |
| 1621 |
Bone Marrow |
Allogeneic |
Genetically Determined Thrombocytopenia |
Hematology |
2024 |
Standard Therapy |
Poland |
4 |
| 1622 |
Bone Marrow |
Allogeneic |
High Risk Acute Myeloid Leukaemia |
Hematology |
2024 |
Standard Therapy |
Poland |
13 |
| 1623 |
Bone Marrow |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Poland |
32 |
| 1624 |
Bone Marrow |
Allogeneic |
Inherited Metabolic Disease |
Hematology |
2024 |
Standard Therapy |
Poland |
11 |
| 1625 |
Bone Marrow |
Allogeneic |
Mds-Rcc Relapse |
Hematology |
2024 |
Standard Therapy |
Poland |
14 |
| 1626 |
Bone Marrow |
Allogeneic |
Mixed Cellularity Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Poland |
43 |
| 1627 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
14 |
| 1628 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
8 |
| 1629 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
14 |
| 1630 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
67 |
| 1631 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
9 |
| 1632 |
Bone Marrow |
Allogeneic |
Osteopetrosis type B |
Hematology |
2024 |
Standard Therapy |
Poland |
13 |
| 1633 |
Bone Marrow |
Allogeneic |
Other Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
9 |
| 1634 |
Bone Marrow |
Allogeneic |
Primary Immunodeficiency |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1635 |
Bone Marrow |
Allogeneic |
Primary Immunodeficiency Xlp-1 |
Hematology |
2024 |
Standard Therapy |
Poland |
18 |
| 1636 |
Bone Marrow |
Allogeneic |
Relapse T-Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
12 |
| 1637 |
Bone Marrow |
Allogeneic |
Secondary Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
4 |
| 1638 |
Bone Marrow |
Allogeneic |
Secondary Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
15 |
| 1639 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1640 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
3 |
| 1641 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
10 |
| 1642 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
21 |
| 1643 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
18 |
| 1644 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
49 |
| 1645 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
16 |
| 1646 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
24 |
| 1647 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
13 |
| 1648 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
14 |
| 1649 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
21 |
| 1650 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
7 |
| 1651 |
Bone Marrow |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2024 |
Standard Therapy |
Poland |
2 |
| 1652 |
Bone Marrow |
Allogeneic |
Severe Congenital Neutropenia |
Hematology |
2024 |
Standard Therapy |
Poland |
1 |
| 1653 |
Bone Marrow |
Allogeneic |
Shwachman-Diamond Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
10 |
| 1654 |
Bone Marrow |
Allogeneic |
Sickle Cell Disease |
Hematology |
2024 |
Standard Therapy |
Poland |
9 |
| 1655 |
Bone Marrow |
Allogeneic |
Biphenotypic Acute Leukemia |
Hematology |
2024 |
Standard Therapy |
Ukraine |
10 |
| 1656 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
58 |
| 1657 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
12 |
| 1658 |
Bone Marrow |
Allogeneic |
hemophagocytic lymphohistiocytosis |
Hematology |
2024 |
Standard Therapy |
Sweden |
4 months |
| 1659 |
Bone Marrow |
Allogeneic |
Severe combined immunodeficiency |
Hematology |
2024 |
Standard Therapy |
Germany |
1 |
| 1660 |
Bone Marrow |
Allogeneic |
Beta-Thalassemia Major |
Hematology |
2024 |
Standard Therapy |
India |
11 |
| 1661 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Austria |
4 |
| 1662 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Norway |
33 |
| 1663 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Spain |
16 |
| 1664 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Switzerland |
5 |
| 1665 |
Bone Marrow |
Allogeneic |
T- Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Ireland |
6 |
| 1666 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
12 |
| 1667 |
Bone Marrow |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2024 |
Standard Therapy |
USA |
4 months |
| 1668 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Belgium |
50 |
| 1669 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
France |
31 |
| 1670 |
Bone Marrow |
Allogeneic |
Chronic myelomonocytic leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
64 |
| 1671 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
France |
10 |
| 1672 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
12 |
| 1673 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
4 |
| 1674 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Canada |
8 |
| 1675 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
Poland |
17 |
| 1676 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
USA |
8 |
| 1677 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
USA |
67 |
| 1678 |
Bone Marrow |
Allogeneic |
Hodgkins Lymphoma |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
36 |
| 1679 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
72 |
| 1680 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
9 |
| 1681 |
Bone Marrow |
Allogeneic |
Chronic Granulomatous Disease |
Hematology |
2024 |
Standard Therapy |
USA |
3 |
| 1682 |
Apheresis |
Allogeneic |
A- Thalassemia |
Hematology |
2024 |
Standard Therapy |
Poland |
11 |
| 1683 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
13 |
| 1684 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
21 |
| 1685 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
22 |
| 1686 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
38 |
| 1687 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
41 |
| 1688 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
44 |
| 1689 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
44 |
| 1690 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
48 |
| 1691 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
50 |
| 1692 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
50 |
| 1693 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
55 |
| 1694 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
59 |
| 1695 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
60 |
| 1696 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
63 |
| 1697 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
44 |
| 1698 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
59 |
| 1699 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
51 |
| 1700 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
34 |